A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Verastem, Inc.
- Study ID
- NCT07644559
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- G12D Mutated KRAS
- Pancreatic Ductal Adenocarcinoma (PDAC)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- VS-7375 — DRUGTaken by mouth
- cetuximab — DRUGSubcutaneous infusion
Study Details
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
Key Dates
- Start date
- Jun 30, 2026
- Status verified
- Jun 2026
- Primary completion
- Jun 30, 2027
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 180 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: VS-7375 Monotherapy
- Experimental: VS-7375 + cetuximab 2L PDAC
- Experimental: VS-7375 + cetuximab 1L PDAC
Primary Outcome Measure
Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 [ Time Frame: 6 months ]
Central Contacts
- Verastem Call Center7812924204
- Luke Chung, MD
Locations (8)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| START- Los Angeles | Los Angeles | California | 90025 | Hope Team Navid Hafez, MD (PRINCIPAL_INVESTIGATOR) |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Brianna Holder Dae-Won Kim, MD (PRINCIPAL_INVESTIGATOR) |
| START Midwest | Grand Rapids | Michigan | 49546 | Hope Team Sreenivasa Chandana, MD (PRINCIPAL_INVESTIGATOR) |
| Washington University | St Louis | Missouri | 63110 | Olive Pressey Kian-Huat Lim, MD (PRINCIPAL_INVESTIGATOR) |
| START New Jersey | East Brunswick | New Jersey | 08816 | Hope Team Bruno Fang, MD (PRINCIPAL_INVESTIGATOR) |
| START Dallas | Fort Worth | Texas | 76104 | Hope Team Salwan Almutar, MD (PRINCIPAL_INVESTIGATOR) |
| START- San Antonio | San Antonio | Texas | 78229 | Hope Team Drew Rasco, MD (PRINCIPAL_INVESTIGATOR) |
| START- Mountain Region | West Valley City | Utah | 84119 | Julianna Daley William McKean, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Los Angeles, CA
Related Studies
- EUS-RFA PANCARDINAL-1 TrialPHASE2 · Recruiting · The University of Texas Health Science Center, Houston · Houston, Texas
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASPHASE1/PHASE2 · Recruiting · Revolution Medicines, Inc. · Orange, California
- KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsPHASE1 · Recruiting · Kura Oncology, Inc. · Phoenix, Arizona
- Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsPHASE1 · Recruiting · Revolution Medicines, Inc. · Sacramento, California